FDA Approves AstraZeneca’s Saphnelo for SLE
AstraZeneca has acquired approval from the U.S. Meals and Drug Administration (FDA) for the subcutaneous self-administration of Saphnelo (anifrolumab-fnia) utilizing the Saphnelo Pen auto-injector for systemic lupus erythematosus (SLE).
The approval permits adults with SLE receiving commonplace remedy to self-inject Saphnelo.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra data
That is supported by outcomes from the Section III TULIP-SC trial, which confirmed that subcutaneous Saphnelo considerably diminished SLE illness exercise in comparison with placebo in sufferers receiving commonplace care.
The noticed security outcomes had been in step with the beforehand established security profile for the intravenous formulation of Saphnelo.
AstraZeneca biopharmaceuticals govt vp Ruud Dobber mentioned: “Since launch, Saphnelo IV infusion has helped tens of hundreds of individuals with systemic lupus erythematosus obtain decrease illness exercise with fewer steroids and has been proven to assist many obtain remission.
“The approval of the Saphnelo pen represents an necessary step ahead in increasing the scientific advantages of Saphnelo to extra folks with systemic lupus erythematosus.”
SLE is an autoimmune illness during which the immune system targets wholesome tissues and organs, resulting in a fancy vary of signs together with fatigue, fever, joint swelling, ache and rash.
Subcutaneous use of Saphnelo is already licensed in Japan and the European Union and stays below regulatory management in a number of different markets. The intravenous route is accepted in additional than 70 international locations.
AstraZeneca acquired international rights to Saphnelo in 2004 by an unique settlement with biopharmaceutical firm Medarex. The co-promotion choice for Medarex expired when it was acquired by Bristol-Myers Squibb (BMS) in 2009.
Underneath the revised 2025 settlement, AstraZeneca will present BMS with royalties on U.S. gross sales within the mid-teens.
Earlier this 12 months, AstraZeneca acquired US approval for Calquence (acalabrutinib) plus venetoclax as the primary fixed-duration all-oral routine for the remedy of adults with continual lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) within the first-line setting.
